Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–8.

Article  CAS  PubMed  Google Scholar 

Eisfeld C, Kajuter H, Moller L, Wellmann I, Shumilov E, Stang A. Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany. BMC Cancer. 2023;23(1):317.

Article  PubMed  PubMed Central  Google Scholar 

Chang-Chan DY, Rios-Tamayo R, Rodriguez Barranco M, Redondo-Sanchez D, Gonzalez Y, Marcos-Gragera R, Sanchez MJ. Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clin Transl Oncol. 2021;23(7):1429–39.

Article  PubMed  Google Scholar 

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hajek R, Schjesvold F, Cavo M, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309–22.

Article  CAS  PubMed  Google Scholar 

Gengenbach L, Graziani G, Reinhardt H, Rosner A, Braun M, Moller MD, Greil C, Wasch R, Engelhardt M. Choosing the right therapy for patients with relapsed/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors. Cancers (Basel). 2021, 13(17): 4320.

Zhao F. Surrogate end points and their validation in oncology clinical trials. J Clin Oncol. 2016;34(13):1436–7.

Article  PubMed  Google Scholar 

Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics].

Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck H-J, Mackey JR, Nabholtz J-M, Paridaens R, Biganzoli L, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987–92.

Article  CAS  PubMed  Google Scholar 

Hashim M, Pfeiffer BM, Bartsch R, Postma M, Heeg B. Do surrogate endpoints better correlate with overall survival in studies that did not allow for crossover or reported balanced postprogression treatments? An application in advanced non-small cell lung cancer. Value Health. 2018;21(1):9–17.

Article  PubMed  Google Scholar 

Dima D, Dower J, Comenzo RL, Varga C. Evaluating daratumumab in the treatment of multiple myeloma: safety, efficacy and place in therapy. Cancer Manag Res. 2020;12:7891–903.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol. 2015;16(1):e32–42.

Article  PubMed  Google Scholar 

Lin Y. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. In: Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting: June 2–6, 2023; Chicago, IL; 2023.

Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, Jin SW, Chen YX, Cao XM, Yang Y, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15(1):86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23(1):65–76.

Article  CAS  PubMed  Google Scholar 

Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J Clin Oncol. 2018;36(25):2593–602.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu J, Yang Y, Tao J, Wang SL, Chen B, Dai JR, Hu C, Qi SN, Li YX. Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. Leukemia. 2020;34(10):2576–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29(8):1822–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi Q, Sargent DJ. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol. 2009;14(2):102–11.

Article  PubMed  Google Scholar 

Chen EY, Haslam A, Prasad V. FDA acceptance of surrogate end points for cancer drug approval: 1992–2019. JAMA Intern Med. 2020;180(6):912–4.

Article  PubMed  PubMed Central  Google Scholar 

Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231–9.

Article  CAS  PubMed  Google Scholar 

Cartier S, Zhang B, Rosen VM, Zarotsky V, Bartlett BJ, Mukhopadhyay P, Wagner S, Davis C. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data. Oncol Res Treat. 2015;38(3):88–94.

Article  CAS  PubMed  Google Scholar 

Félix J, Aragão F, Almeida JM, Calado FJ, Ferreira D, Parreira AB, Rodrigues R, Rijo JF. Time-dependent endpoints as predictors of overall survival in multiple myeloma. BMC Cancer. 2013;13:122.

Article  PubMed  PubMed Central  Google Scholar 

Lee SJ, McQueen RB, Beinfeld M, Fluetsch N, Whittington MD, Pearson SD. DA O: Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma; final evidence report. In: Institute for Clinical and Economic Review, May 11, 2021.

Beinfeld M, Lee S, McQueen B, Fluetsch N, Pearson SD, Ollendorf DA. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma. J Manag Care Spec Pharm. 2021;27(9):1315–20.

PubMed  Google Scholar 

Dimopoulos M. Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma. In: Presented at ISPOR: November 4–8, 2017; Glasgow, Scotland.

Zar JH. Spearman rank correlation. In: Encyclopedia of biostatistics. Volume 7, edn. Edited by Armitage P, Colton T. Hoboken, NJ: John Wiley and Sons, Ltd; 2005.

Wooldridge JM. Introductory econometrics: a modern approach. Mason, Ohio: South-Western, Cengage Learning; 2012.

Google Scholar 

Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29(6):1102.

Article  CAS  PubMed  Google Scholar 

Lousdal ML. An introduction to instrumental variable assumptions, validation and estimation. Emerg Themes Epidemiol. 2018;15:1.

Article  PubMed  PubMed Central  Google Scholar 

Choi S, Choi T, Cho H, Bandyopadhyay D. Weighted least-squares regression with competing risks data. Stat Med. 2022;41(2):227–41.

Article  PubMed  Google Scholar 

McLeod C, Norman R, Litton E, Saville BR, Webb S, Snelling TL. Choosing primary endpoints for clinical trials of health care interventions. Contemp Clin Trials Commun. 2019;16:100486.

Article  PubMed  PubMed Central  Google Scholar 

Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health. 2017;20(3):487–95.

Article  PubMed  Google Scholar 

Bognar K, Romley JA, Bae JP, Murray J, Chou JW, Lakdawalla DN. The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions. J Health Econ. 2017;51:1–12.

Article  PubMed  Google Scholar 

Zhang J, Pilar MR, Wang X, Liu J, Pang H, Brownson RC, Colditz GA, Liang W, He J. Endpoint surrogacy in oncology phase 3 randomised controlled trials. Br J Cancer. 2020;123(3):333–4.

Article  PubMed  PubMed Central  Google Scholar 

Chen EY, Joshi SK, Tran A, Prasad V. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials. JAMA Intern Med. 2019;179(5):642–7.

Article  PubMed  PubMed Central  Google Scholar 

Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007;25(29):4562–8.

Article  PubMed  Google Scholar 

Cornell RF, Kassim AA. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transpl. 2016;51(4):479–91.

Article  CAS  Google Scholar 

Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, et al. Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019;37(14):1228–63.

Article  PubMed  Google Scholar 

Mejia Saldarriaga M, Darwiche W, Jayabalan D, Monge J, Rosenbaum C, Pearse RN, Niesvizky R, Bustoros M. Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. Front Oncol. 2022;12:1020011.

Article  PubMed  PubMed Central